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Effect of conjugated estrogens on platelet function and prostacyclin
generation in CRF. In a double-blind, randomized, placebo-controlled
cross-over study, we investigated in seven patients with chronic renal
failure the effect of conjugated estrogens (0.6 mg/kg/day for 5 days) on
template bleeding time and on thromboxane A2 (TxA2), -thromboglo-
bulin (/3-TG) and prostacyclin (PGl) concentrations in blood emerging
from the template bleeding time incisions. Administration of conjugated
estrogens resulted in a significant shortening of the bleeding time in six
out of seven patients with a maximum effect 7 and/or 14 days following
treatment. Both TxA2 (measured as thromboxane B,. TxB2) and 13-TG
release in bleeding time blood were significantly higher following
administration of conjugated estrogens as compared to placebo admin-
istration. No difference was seen in endothelial PGI2 (measured as
6-keto.prostaglandin F10) formation when patients were treated with
conjugated estrogens as compared to placebo administration over the 28
day observation period. We conclude that in patients with chronic renal
failure, infusion of conjugated estrogens results in a significant short-
ening of the bleeding time together with an increase in platelet reactiv-
ity, as indicated by an increase of TxA, and /3-TG concentration in the
microvasculature. No effect was seen on P612 production, thereby
excluding a major effect on vascular prostaglandin metabolism.
A large body of evidence indicates that the pathogenesis of
the bleeding tendency in patients with chronic renal failure is
multifactorial, eventually leading to an impairment of the inter-
action of blood platelets with the vessel wall [reviewed in I].
The grossly prolonged bleeding time found in these patients is
attributed to the severe chronic anemia usually present in
patients with end-stage chronic renal failure [21, an acquired
abnormality in platelet function [3—91, and/or an increased
synthesis of prostacyclin by the vasculature [9—Il]. Various
therapeutic strategies have been recommended for uremic
bleeding complications: the value of hemodialysis or peritoneal
dialysis has not yet been fully established [12, 131. The effect of
transfusion of red cells, platelets or cryoprecipitate is often
limited and, moreover, bears the risk of transmitting viral
infections such as hepatitis or the acquired immunodeficiency
syndrome [141. Infusion of desmopressin (l-deamino-8-D-argi-
nine vasopressin) has been reported to significantly shorten the
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bleeding time, but its effect is only of a limited duration [15].
Recently, the administration of conjugated estrogens has been
shown not only to cause a significant shortening of the bleeding
time, lasting for as long as two weeks, but also to prevent
uremic bleeding following surgery [16—18). However, the mech-
anism by which conjugated estrogens exert these effects is by
no means clear.
We have recently reported on a technique which consists of
the measurement of mediators of hemostasis in blood emerging
from a standardized injury of the vasculature made to determine
template bleeding time [19—21]. The randomized placebo-con-
trolled, double-blind cross-over study presented in this paper
has been designed not only to investigate the effect of the
administration of conjugated estrogens on the bleeding time in
patients with end-stage renal failure, but also to gain insight into
some of mechanisms by which conjugated estrogens might
influence platelet plug formation in chronic renal failure. This
paper reports the generation of three of these mediators—
thromboxane B2 (TxB2) as an end-product of platelet cyclooxy-
genase activity [22], 6-keto.prostaglandin Fia(6-keto-PGF1,) as
an index for vascular prostacyclin (PGI2) generation [23], and
3-thromboglobulin (J3-TG) as an indicator for the platelet alpha-
granule release [24]—in the microvasculature of patients with
chronic renal failure after treatment with conjugated estrogens.
Methods
Subjects
The study group consisted of seven patients (4 male, 3
female; median age 52, range 39 to 76) with end-stage chronic
renal failure. Uremia was due to chronic glomerulonephritis in
three patients, chronic pyelonephritis in three patients and
polycystic kidney disease in one patient. All patients had been
on regular maintenance hemodialysis (3 sessions per weeks for
4 hours, 1.2 m2 Cuprophan capillaries, Gambro Fiber GFS, 120
H, Gambro, Sweden) for a median period of 12 months (range
Ito 16 months). Prior to the study period the median predialysis
platelet count, hematocrit value and serum creatinine level
were l49,000/pi (range 109,000 to 389,000), 27.9% (18.7 to 27.9)
and 11.1 mg/dl (7.9 to 12.8), respectively. Coagulation param-
eters (prothrombin time, partial thromboplastin time, fibrinogen
concentration) were within the normal range throughout the
study period (data not shown). The patients had not ingested
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any drugs known to interfere with platelet function for at least
two weeks before the study as well as throughout the study
period. In order to investigate a homogenous study group
patients without medical problems which could influence plate-
let function such as diabetes mellitus or hypertension were
recruited. This was the major reason for the relatively small
sample size. However, minor subclinical alterations in the
actual state of disease in these chronically ill patients could not
be excluded. All patients gave written consent and the study
was approved by the Hospital Ethics Committee.
Study design
The study was performed as a double-blind, randomized,
placebo-controlled, cross-over trial. The patients were given
0.6 mg/kg of body weight of conjugated estrogens (a mixture of
sodium estrone sulfate (51%), sodium equiline sulfate (22%),
dihydroequiline sulfate (16%), equiline sulfate (5%) and es-
trostiol sulfate (6%); Premarin', Arcana Company, Spittal/
Drau, Austria); or placebo (saline) on five consecutive days
starting 24 hours after the previous hemodialysis session. Thus,
the total dosage of conjugated estrogens was 3 mg/kg of body
weight. Estrogen or placebo was added to 50 ml of saline and
infused over a period of half an hour. No side effects of
conjugated estrogen treatment were observed throughout the
study period. However, since the study group consisted only of
a small number of patients, the occurrence of side effects of
conjugated estrogen treatment could not be generally ruled out.
After a wash out period of at least eight weeks the patients
crossed over to the alternative treatment.
Bleeding time, sampling of bleeding time blood and collection
of venous blood samples were performed 7, 14, 21 and 28 days
following initiation of estrogen and placebo administration.
Bleeding time and sampling of bleeding time blood
Template skin bleeding time was determined according to the
technique of Mielke et a! [25] using a disposable standard device
(Simplate II, General Diagnostics, New Jersey, USA). Two
incisions, 5 mm long and 1 mm deep, were made at the lateral
aspect of the volar surface of the forearm parallel to the
antecubital crease. Results are given as the mean bleeding time
of the two incisions (normal range 3 to 9 mm). The bleeding time
was recorded for a maximum of 20 minutes.
Blood emerging from the incision was collected as described
recently [9, 19, 201. By the use of a Glison 200 d pipette blood
was collected directly from the bleeding time wounds in 30
second intervals and processed in aliquots corresponding to
one-minute time intervals. The bleeding time blood was imme-
diately passed into ice-cold Eppendorf tubes (1 tube/mm) con-
taining an anticoagulant mixture consisting of 100 m ethylene-
diamine tetraacetic acid (EDTA), 30 M indomethacin (Sigma
Chemical Corporation Limited, Kalamazoo, Michigan, USA),
300 nM 6-oxo-prostaglandin E1 (provided by Dr. J. Westwick,
Hunterian Institute, Department of Pharmacology, Royal Col-
lege of Surgeons, London, UK), 1000 U/mI aprotinin (Tra-
sylol', Bayer AG, Leverkusen, FRG) and 1500 U/mI sodium
heparin (Novo Industri, Kopenhagen, Denmark). After mixing,
the tubes were centrifuged at 12,000 g for one minute. The
supernatant was stored at —80°C.
Table 1. Template bleeding timea in patients with chronic renal
failure 7 to 28 days following administration of conjugated estrogens(CE 0.6 mg kg_I day' for 5 days) or placebo (P)
Patient
number
Day
CE
7
P
Day
CE
14
P
Day
CE
21
P
Day
CE
28
P
I 12 17 12 14 9 18 15 15
2 20I 20 20 20 20 20 20 20
3 8 20 13 20 16 20 20 20
4 15 20 13 20 16 13 20 20
5 7 7 10 15 12 14 16 13
6 7 8 6 12 II 9 12 8
7 9 14 9 20 6 13 15 15
Mean 11° 15 ,2d 17 13 IS 17 16
SEM 1.7 2.0 1.5 1.1 1.5 1.5 1.1 1.4
Bleeding time values in minutes
b For a bleeding time of more than 20 mm, a value of 20 mm was
assumed in order to calculate means SEM.
P = 0.04d P = 0.03
Assays
Platelet counts, serum creatinine concentrations and hema-
tocrit levels were determined by routine methods. f3-TG con-
centrations were measured by the use of a commercially
available radioimmunoassay procedure (/3-TG RIA kit, Amer-
sham International, Amersham, UK). According to the manu-
facturers instructions the intra- and interassay variabilities of
the assay procedure are 7.5% and 9.9% to 15.3%, respectively.
TxB2 and 6-keto-PGF1a levels were measured by radioimmu-
noassay [26, 27]. Rabbit anti-TxB2 antiserum and sheep anti-6-
keto-PGF, antiserum, TxB2 and 6-keto-PGF1Q were from Dr.
John Westwick (Hunterian Institute, London, UK). 3H-TxB2
and 3H-6-keto-PGF1,, (100 to 140 mCi/mmol, respectively) were
obtained from New England Nuclear (Southampton, UK). For
the TxB, radioimmunoassay procedure, the intra- and interas-
say variabilities in our laboratory were 10.5% and 12%, respec-
tively. For the 6-keto-PGF1, radioimmunoassay procedure the
corresponding values were 10.4% and 10.75%. The detection
limit for both tests was 20 pg/mI.
Statistical analysis
Statistical analysis was carried out by a repeated-measures
analysis of variance. In addition descriptive methods concern-
ing the differences between conjugated estrogens and placebo
of the different time points were used [28, 29].
Results
Bleeding time
The effect of conjugated estrogens on the template skin
bleeding time is given in Table I. Seven and 14 days following
administration of conjugated estrogens the mean bleeding time
was 11 and 12 minutes, respectively, whereas the correspond-
ing values after placebo were 15 (P = 0.04) and 17 (P = 0.03)
minutes. Only a slight effect was noted after 21 days, and no
effect was observed after 28 days.
Following conjugated estrogen treatment a marked response
of the bleeding time was seen in three patients (patient 3, 4 and
7) up to 14 days following initiation of therapy. In two patients
(Patient I and 7) a normalization was observed after 21 days. In
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Table 2. Release of /3-TO in the microcirculation of patients with
chronic renal failure following conjugated estrogens (CE, 0.6 mg/kg!
day over 5 consecutive days) or placebo, P
Patient
number
D
CE
ay 7
P
Day
CE
14
P
Day 21
CE P
Day 28
CE P
1 3.3 2.7 4.0 2.8 5.5 3.2 3.8 2.6
2 2.0 2.3 2.5 2.1 3.6 1.9 2.2 1.8
3 4.7 2.8 2.7 1.7 3.6 2.3 2.9 2.3
4 3.5 3.0 2.6 2.9 3.0 2.6 3.4 2.7
5 7.4 5.6 6.9 4.1 6.4 4.2 7.0 6.1
6 5.3 3.8 4.2 3.8 5.3 3.4 3.7 3,1
7 2.2 3.6 2.3 1.6 3.3 2.1 2.9 2.1
Mean 4.1 3.4 3.6 2.7 4.4 2.8 3.7 3.0
SEM 0.7 0.4 0.6 0.4 0.5 0.3 0.6 0.5
P values 0.2 0.06 0.0008 0.0002
In each patient blood was sampled from a template bleeding time
incision in one minute aliquots over 4 minutes 7, 14, 21 and 28 days
following conjugated estrogens and placebo. The /3-TG concentration
was determined for each minute and the area under the concentration
curve is regarded as the amount of /3-TO-production (given in tg/
platelets x 105/min) at each occasion.
Table 3.
chronic re
Generation of TxB2 in the microcirculation of patients with
nal failure following conjugated estrogens (CE, 0.6 mg/kg!
day over 5 consecutive days) or placebo (P)
Patient Day 7 Day 14 Day 21 Day 28
number CE P CE P CE P CE P
1 10.5 6.7 7.3 10.3 15,3 5.1 15.9 3.6
2 5.7 7.1 5.0 1.5 10.8 2.5 7.3 5.3
3 14.8 3.0 6.2 3.3 10.8 3.7 4.3 1.9
4 23.8 16.0 8.3 12.8 13.8 11.4 20.0 12.0
5 25.7 24.0 26.1 16.4 26.5 18.6 20.9 23.3
6 9.1 5.3 8.5 4.1 15.1 8.2 4.7 2.8
7 4.2 5.4 5.4 3.8 4.8 5.0 3.5 5.6
Mean 13.4 9.6 9.5 7.5 13.9 7.8 11.0 7.8
SEM 3.2 2.9 2.8 2.2 2.5 2.1 2.9 2.9
P values 0.08 0.3 0.004 0.16
In each patient blood was sampled from a template bleeding time
incision in one minute aliquots over 4 minutes 7, 14, 21 and 28 days
following conjugated estrogens and placebo. The TxB2 concentrations
were determined and the area under the concentration curve was
regarded as the amount of TxB2 generation (given in ng/platelets x
105/min) at each occasion.
one patient (Patient 2) the bleeding time was> 20 minutes, both
following placebo or conjugated estrogens.
13-TG, TxB2 and 6-keto-PGF,a concentrations in blood
obtained from the bleeding incisions
The effect of conjugated estrogens on /3-TG, TxB2 and
6-keto-PGF1 formation in blood obtained from the bleeding
incisions is given in Tables 2 through 4. To exclude major
artefactual changes in the platelet-derived parameters due to
variations in the platelet counts at different observation time
points in the same patient as a consequence of his actual state
of disease, /3-TG and TxB2 concentrations are given in ng and
pg/b5 platelets rather than in nglml and pg/mI, respectively. At
each occasion, that is, 7, 14, 21 and 28 days following estrogen
or placebo administration, blood from the bleeding time inci-
sions was collected in one minute aliquots over four minutes.
For each minute, the concentrations of f3-TG, TXB2r, and
6-keto-PGF1 in bleeding time blood were measured and the
Table 4. Generation of 6-keto-PGF1, in the microcirculation of
patients with chronic renal failure following conjugated estrogens
(CE; 0.6 mg/kg/day over 5 consecutive days) or placebo (P)
Patient Day 7 Day 14 Day 21 Day 28
number CE P CE P CE P CE P
544 162 529 621 411 404 343 442
2 1130 927 990 780 818 696 853 577
3 733 425 434 356 393 569 329 389
4 246 183 246 512 202 241 321 411
5 640 582 623 206 609 518 559 474
6 1308 713 512 234 669 418 952 347
7 205 370 176 161 331 93 154 193
Mean 687 480 501 410 490 420 501 405
SEM 157 106 101 89 81 77 123 45
P values 0.07 0.04 0.26 0.36
In each patient blood was sampled from a template bleeding time
incision in one minute aliquots over 4 minutes 7, 14, 21 and 28 days
following conjugated estrogens and placebo. The 6-keto-PGF1 concen-
trations were determined and the area under the concentration curve
was regarded as the amount of 6-keto-PGF1, generation (given in
pg/mt/mm) at each occasion.
area under the corresponding concentration curve was regarded
as the amount of mediator production in the microvasculature.
Following placebo administration no statistically significant
differences in bleeding time /3-TG, TxB2 and 6-keto-PGF1
concentrations were found throughout the study period.
The mean area under the J3-TG concentration curve over the
28-day study period was significantly higher (P = 0.0056)
following treatment with conjugated estrogen compared to
placebo administration (Table 2). A considerable—though not
statistically significant—increase was noted already 7 days
(from 3.4 to 4.1 ng!105 platelets/mm, P =0.2) and 14 days (from
2.7 to 3.6 ng/105 platelets, P = 0.06) following conjugated
estrogens compared to placebo. Twenty-one and 28 days fol-
lowing initiation of treatment an increase of the corresponding
mean /3-TG values from 2.8 to 4.4 ng/l05 platelets/mm (P =
0.0008) and from 3.0 to 3.7 ng/105 platelets/mm (P = 0.0002),
respectively, was observed. An enhancement of a-granule
release was seen in six out of seven patients 14 days and in all
7 patients 21 and 28 days after conjugated estrogen treatment.
The modest effect of conjugated estrogens was seen in those
patients (Patients 2, 3 and 4) with the longest bleeding times
three and four weeks following treatment.
Over the 28-day study period production of TxB2 in the
microvasculature of patients with chronic renal failure was
significantly higher (P = 0.037) after conjugated estrogen ther-
apy as compared to placebo treatment (Table 3). The mean
TxB2 concentration in bleeding time blood increased from 9.62
to 13.38 ng/l05 platelets/mm after seven days (P = 0.08), from
7.45 to 9.53 ng!l05 platelets/mm after 14 days (P = 0.3), from
7.77 to 13.86 ng!l05 platelets/mm after 21 days (P = 0.0004) and
from 7.79 to 10.96 ng!105 platelets/mm after 28 days (P =0.16)
when patients were given conjugated estrogens compared to
placebo administration. An increase in thromboxane formation
was seen in five out of seven patients 14 and 28 days and in six
out of seven patients 21 days following conjugated estrogens
compared to placebo.
6-keto-PGF1 a concentrations were slightly but not statisti-
cally significantly (P = 0.1182) elevated throughout the 28-day
study period in the patients with chronic renal failure after
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conjugated estrogen treatment compared to placebo (Table 4).
Seven days after initiation of treatment the mean 6-keto-PGF1a
concentration was 687 pg/mI/mm when patients were given
conjugated estrogens and 480 pg/mI/mm when patients were
given placebo (P = 0.07). Two, three and four weeks after
conjugated estrogen therapy only a minor increase in bleeding
time 6-keto-PGF1a was observed: from 410 to 501 pg/mI/mm
after 14 days (P = 0.03), from 420 to 490 pg/mI/mm after 21 days
(P = 0.26), and from 405 to 501 pg/mI/mm after 28 days (P =
0.36).
Discussion
Conjugated estrogens have been shown to shorten the tem-
plate bleeding time and to control postoperative bleeding in
patients with chronic renal failure [16—18]. In an attempt to gain
further insight into the mechanisms of action of this substance,
we have evaluated in uremic patients the effect of conjugated
estrogens on the platelet release reaction and on the vascular,
and platelet prostaglandin mechanism using a newly developed,
in vivo technique. This method consists of the measurement of
mediators of hemostasis locally at the site of platelet-vessel wall
interaction, that is, in blood emerging from a standardized
injury of the microvasculature made to determine skin bleeding
time [9, 20, 21]. In a double-blind, randomized, placebo-
controlled cross-over trial, we have administered a total dose of
3 mg/kg of conjugated estrogens (or placebo) in 24 hour inter-
vals over five days, since only this estrogen regimen has been
shown to exhibit a long lasting effect on the bleeding time [18].
A shortening of the bleeding time was observed in the
majority of patients over 7 and/or 14 days, and in two subjects
even 21 days following conjugated estrogen therapy compared
to placebo administration. No effect was seen in one patient
who had a bleeding time of more than 20 minutes following both
placebo and conjugated estrogens. Twenty-eight days following
initiation of therapy the bleeding times after conjugated estro-
gen therapy were similar compared to placebo administration.
It has to be considered that in patients with an acquired platelet
defect, such as in patients with chronic renal failure, the
bleeding time may be affected by the actual state of the
underlying disease. This may explain the variability of the
bleeding time in some patients seen throughout the 28 day study
period following administration of placebo. Our data confirm
previous observations [16—18] and indicate that treatment with
conjugated estrogens leads in the majority of uremic patients to
a shortening, sometimes even to a normalization of the bleeding
time. However, the lack of effect in one of our patients
following conjugated estrogen administration might suggest that
a subset of patients exists in whom this substance is less
effective.
The template skin bleeding time is the most valuable screen-
ing test for the assessment of platelet plug formation [30]. Thus,
it seemed justified to anticipate that the measurement of medi-
ators in blood emerging from such a microvascular injury might
further elucidate some of the mechanisms leading to an abnor-
mal platelet vessel wall interaction in patients with a hemor-
rhagic diathesis due to impaired platelet function. Indeed, we
were recently able to show an increase in prostacyclin forma-
tion and an impairment of the alpha-granule release in patients
with chronic uremia [9]. The observation of a shortening of the
bleeding time in patients with chronic renal failure following
administration of conjugated estrogen led us to investigate the
effect of this substance on vascular and platelet prostaglandin
metabolism and on alpha-granule release under in vivo circum-
stances.
An increase in the production of PGI2—a potent platelet
antiaggregatory agent and vasodilator [231—by the vascular
endothelium has previously been shown in humans [311 and in
animals [32] cx vivo following estrogen administration. There-
fore it has been speculated that in the patients with chronic
renal failure, conjugated estrogens might act by diminishing
endothelial prostacyclin release. However, our data of a similar
PGI2 generation following estrogens as compared to placebo
indicate that conjugated estrogens do not exhibit a major effect
on the vascular prostaglandin metabolism. This is in good
agreement with Zoja et al [33], who did not observe an
association between PG!2 generation and conjugated estrogen
injection in a rat model of uremia that reproduced hemostatic
abnormalities of uremic humans, such as prolonged bleeding
time and increased vascular PG!2 production.
In patients with chronic renal failure, we have recently found
a marked decrease in /3-TG release and a moderate reduction in
TxB, formation at the site of platelet vessel wall interaction,
indicating an acquired platelet dysfunction as one of the under-
lying causes for bleeding in chronic uremia [9]. When these
patients were given conjugated estrogens a marked increase in
bleeding time /3-TO and TxB2 concentrations was found over a
28 day period compared to placebo administration. The effect of
conjugated estrogens on the concentration of platelet-derived
compounds was noted already after 7 and 14 days and lasted
over the whole observation period to a similar extent. In
particular, microvascular 13-TG concentrations were higher in
all seven patients 21 and 28 days after conjugated estrogens
compared to placebo. The absence of a statistically significant
difference 7 and 14 days after treatment could well be explained
by the relatively small sample size. Since the amount of /3-TO
release from the platelet cs-granules is regarded as a sensitive
indicator for platelet activation [341, these findings strongly
suggest that conjugated estrogen treatment is associated with a
marked increase in platelet function with a long lasting effect up
to four weeks following treatment. Interestingly, a significant
effect of this substance was seen up to 28 days, a time when a
shortening of the bleeding time was no longer demonstrable.
However, the template bleeding time is not only dependent on
platelet activity but is also influenced by other factors, such as
severe anemia and platelet and plasma von Willebrand factor
defects [35]. Apart from platelet function conjugated estrogens
might exhibit an effect on various other mechanisms involved in
the prolongation of the bleeding time which do not show up in
the technique used in this investigation. Another explanation
could be a higher sensitivity of the technique applied in this
study compared to the template bleeding time as a global test of
primary hemostasis. However, the observation of the smallest
increase in bleeding time /3-TO in those patients with the longest
bleeding times 21 and 28 days following estrogen administration
suggests at least a weak relationship between bleeding time and
indicators of platelet reactivity determined in the microcircula-
tion.
The discrepancy between the plasma half-life of conjugated
estrogens of a few hours and its long lasting effect on platelet
activity can be explained by the proposed model of estrogen
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action, which suggests an estrogen receptor-mediated mecha-
nism. There is evidence that endothelial and mononuclear cells
posess estrogen receptors [36, 37]. Therefore, one can specu-
late that these cells could be the first target of estrogen action on
uremic bleeding. These primary target cells could elaborate
message(s) which enhance platelet reactivity in the microvas-
culature, eventually leading to increased TxB2 and 13-TG con-
centrations. From our data we cannot differentiate whether the
increase in TxB2 is due to a direct effect on the platelet
prostaglandin metabolism or the consequence of an overall
enhancement of platelet function following administration of
this substance.
In conclusion, in patients with chronic renal failure the
administration of conjugated estrogen at a dose of 0.6 mg/kg!
day over five days results not only in a shortening of the
bleeding time, but also in a long lasting increase of f3-TG and
TxB2 formation in the microvasculature, whereas no effect on
endothelial PG!2 generation was observed. These observations
indicate that conjugated estrogens may act by enhancing plate-
let reactivity rather than by diminishing endothelial PG!2 pro-
duction. Further clinical studies are necessary to evaluate
whether the effect of conjugated estrogens on bleeding time and
on mediator production in the microvasculature is related to a
beneficial therapeutic effect in case of uremic bleeding epi-
sodes.
Acknowledgments
Rabbit anti-TxB2 antiserum, sheep anti-6-keto-PGF1 antiserum.
TxB2, 6-keto PGF1a and 6-oxo-prostaglandin E1 used in this study was
a gift from Dr. J. Westwick. Hunterian Institute, Department of
Pharmacology, Royal College of Surgeons, London. England. United
Kingdom.
Reprint requests to Dr. P. A. Kyr!e, I. Med. Univ. Klinik, Germ-
nungslabor, Lazarettgasse /4, /090 Vienna, Austria.
References
I. REMUZZI G: Bleeding in renal failure. Lancet i:1205—1208, 1988
2. Livio M, MARCHESI D, REMLJZZI G, GOTTI E, MECCA G, DE
GAETANO G: Uraemic bleeding: Role of anaemia and beneficial
effect of red cell transfusions. Lancet ii:1013—l015, 1982
3. SALZMAN EW, NERI LL: Adhesiveness of blood platelets in
uremia. Thromb Diath Haemorrh 15:84—92, 1966
4. EKNOYAN G, WACKSMAN SJM, GLUECK HI. WILL ii: Platelet
function in renal failure. N Engi J Med 280:677—681. 1969
5. CASTILLO R, LOZANO T, ESCOLAR G. REVERT L, LOPEZ J, ORDI-
NAS A: Defective platelet adhesion on vessel subendothelium in
uremic patientns. Blood 68:337—342, 1986
6. REMUZZI 0, BENIGN! A, D0DEsINI P. SCHIEPPATI A, Livio M, DE
GAETANO G, DAY JS, SMITH WL, PINCA E, PATRIGNANI P.
PATRANO C: Reduced platelet thromboxane formation in uremia.
Evidence for a functional cyclooxygenase defect. J Clin Invest
71:762—768, 1983
7. Di MINNO G, MARTINEZ J, MCKEAN ML, DE LA ROSA L, BURKE
iF, MURPHY S: Platelet dysfunction in uremia: Multifaceted defect
partially corrected by dialysis. Am J Med 79:552—559, 1985
8. RAO AK: Uraemic platelets. Lancet i:913—914, 1986
9. KYRLE PA, STOCKENHUBER F, BRENNER B, GOSSINGER H, KORN-
INGER C, PABINGER I, SUNDER-PLASSMANN G, BALCKE P. LECH-
NER K: Evidence for an increased generation of prostacyclin in the
microvasculature and an impairment of the platelet alpha-granule
release in chronic renal failure. Thromb Haemost 60:205—208, 1988
10. REMUZZI G, MARCHESI D, Livo M, LAVENAGHI AE, MECCA G,
DONATI MB, DE GAETANO G: Altered platelet and vascular pros-
taglandin generation in patients with renal failure and prolonged
bleeding times. Thromb Res 13:1007, lOIS, 1978
II. REMUZZI 0, LivIo M, CAVENAGHI AE, MARCHESI D, MECCA G,
DONATI MB, DE GAETANO G: Unbalanced prostaglandin synthesis
and plasma factors in uraemic bleeding: A hypothesis. Thromb Res
13:531—536, 1978
12. STEWART JH, CASTALDI PA: Uremic bleeding: A reversible plate-
let defect corrected by dialysis. Quart J Med 36:409—423, 1967
13. RABINER SF: The effect of dialysis on platelet function of patients
with renal failure. Ann NYAcad Sci 201:234—242, 1972
14. JANSON PA, JUBELIRER Si, WEINSTEIN MJ, DEYKIN D: Treatment
of the bleeding tendency in uremia with cryoprecipitate. N Eng! J
Med 303:1318—1322, 1980
15. MANNUCCI PM, REMUZZI 0, PUSINERI F, LOMBARDI R, VALSEC-
CHI C, MECCA G, ZIMMERMAN TS: Deamino-8-D-arginine vaso-
pressin shortens the bleeding time in uremia. N EngI J Med
308:8—12, 1983
16. Lw YK, KOSFELD RE, MARCUM SG: Treatment of uraemic
bleeding with conjugated oestrogen. Lancet ii:887—890, 1984
17. LIvlo M, MANNUCCI PM, VIGANO 0, MINGARDI G, LOMBARDI R,
MECCA G. REMUZZI G: Conjugated estrogens for the management
of bleeding associated with renal failure. N EngI J Med 315:731—
734, 1986
18. VIGANO G, GASPARI F, LOCATELLI M, PUSINERI F, BONATI M,
REMUZZI G: Dose-effect and pharmacokinetics of estrogens given
to correct bleeding time in uremia. Kidney mt 34:853—858, 1988
19. THORNGREEN M, SHAFI 5, BORN GVR: Thromboxane A2 in skin
bleeding-time blood and in clotted blood before and after adminis-
tration of acetylsalicylic acid. Lancet i: 1075—1078, 1983
20. KYRLE PA, WESTWICK i, SCULLY MF, KAKKAR VV, LEWIS GP:
Investigation of the interaction of blood platelets with the coagula-
tion system at the site of plug formation in vivo in man—effect of
low-dose aspirin. Thromb Haemost 57:62—66, 1987
21. KYRLE PA. EICHLER HG, JAiER U, LECHNER K: Inhibition of
prostacyclin and thromboxane A2 generation by low-dose aspirin at
the site of plug formation in man in vivo. Circulation 75:1025—1029,
1987
22. HAMBERG M, SVEN550N i, SAMUELSSON B: A new group of
biological active compounds derived from prostaglandin endoper-
oxides. Proc Nat! Acad Sci USA 72:2994—2998, 1975
23. MONCADA 5, HIGGS EA, VANE iR: Human arterial and venous
tissues generate prostacyclin (prostaglandin X) a potent inhibitor of
platelet aggregation. Lancet 1:18, 1977
24. LUDLAM CA, MOORE S. BOLTON AE, PEPPER DE, CASH JD: The
release of a human platelet specific protein measured by a radio-
immunoassay. Thromb Res 6:543—553, 1975
25. MIELKE CH. KANESHIRO MM, MAHLER IA, WEINER JM, RAPA-
PORT SI: The standardization Ivy bleeding time and its prolongation
by aspirin. Blood 34:204—215, 1969
26. INGERMAN-W0JENSKI C, SILVER M, SMITH JB, MACARAK E:
Bovine endothelial cells in culture produce thromboxane as well as
prostacyclin. J Clin Invest 67:1292—1296, 1981
27. HENSHY CN, ioGlE M, ELDER Mi, MYATT L: Comparison of the
quantitative analysis of 6-keto-PGF1-alpha on biological fluids by
gas chromatography, mass spectrometry and radioimmunoassay.
Biomed Mass Spectrom 8:111—I 17, 1981
28. WINER Bi: Statistical Principles in Experimental Design. New
York, McGraw Hill, 1971
29. FREUND RJ: SAS System for Linear Models. SAS institute Inc,
1986
30. HARKER LA, SLICHTER Si: The bleeding time as a screening test
for evaluation of platelet function. N EngI J Med 287:155—159, 1972
31. YLIKORKALA 0, PUOLAKKA i, VIINIKKA L: The effect of oral
contraceptives on antiaggregatory prostacyclin and proaggregatory
thromboxane A2 in humans. Am J Obstet Gynecol 142:573—576, 1982
32. ELAM MB, LIPSCOMB GE, CHESNEY CM, TERRAGNO DA, TER-
RAGNO NA: Effect of synthetic estrogen on platelet aggregation an
vascular release on PGI2-like material in the rabbit. Prostaglandin
20: 1039—1051, 1980
33. ZOJA C, VIGANO 0, BERGAMEMELLI A, BENIGNI A, DE GAETANO
0, REMUZZI R: Prolonged bleeding time and increased vascular
prostacyclin in rats with chronic renal failure: effects of conjugated
estrogens. J Lab Clin Med 112:380—386, 1988
1186 Heistinger et a!: Effect of conjugated estrogens on uremic platelets
34. ZAHAVI J, KAKKAR VV: Beta-thromboglobulin—a specific marker 36. RANELLETTI FO, PIANTELLI M, CARBONE A, RINELLI A, SCAMBIA
of in vivo platelet release reaction. Thromb Haemostas 44:23—29, G, PANIcI PB, MANCUSO S: Type 11 estrogen-binding sites and
1980 17/3-hydroxysteroid dehydrogenase activity in human peripheral
35. GRALNICK HR, MCKEOWN LP, WILLIAMS SB, SHAVER BC: blood mononuclear cells. J Clin Endocrinol Metab 67:888—892, 1988
Plasma and platelet von Willebrand defects in uremia. Am J Med 37. COLBURN P, BUONASSISI V: Estrogen-binding sites in endothelial
85:806—810, 1988 cell cultures. Science 201:817—819, 1978
